Biological Treatment Articles & Analysis
8 news found
When the wastewater generated by the pharmaceutical industries has a high organic matter content, Salher’s biological treatment with a moving bed (MBBR) is the most suitable. The particularity of this wastewater is that its micropollutants are resistant to conventional treatments, so in some cases it is necessary to include in the basic ...
BySalher
Haishan Jang, Chairwoman and CEO of BRIM Biotechnology, commented, “Receiving FDA orphan drug designation allows us to proceed confidently with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for NK. Clinically, the treatment of NK is very complicated, and there is a lack of effective and affordable ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. ...
(Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the ...
BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to other radiation, chemotherapy or biological treatment modalities currently in use. Neutron Therapeutics Inc. and the Helsinki University Hospital are collaborating to launch the first ...
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of ...
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. SLE ...
"Results of this study provide further clinical evidence of the potential for mirikizumab to become the first anti-IL-23p19 biologic for the treatment of ulcerative colitis." In LUCENT-1, mirikizumab met the primary endpoint of clinical remission at Week 12 compared to placebo (p Mirikizumab also achieved all key secondary endpoints compared to placebo at Week ...